

STIMULAN® Competitive Environment

In-person training for Canada Distributor Sales Representatives



Training objectives

At the end of this 20 minute training session you will:

- Know who the key competitors are for STIMULAN in the infection market
- Understand the key characteristics of their products and positioning
- Be aware of their strengths and weaknesses relative to STIMULAN
- Know which differentiating factors to focus on in conversations with your surgeons
- Have an action plan for increasing STIMULAN sales



Agenda

- Infection market
- Competitor differentiation summary
- Product profiles:
 - Collatamp® G
 - OSTEOSET® T
 - Cerament® G
 - STIMULAN
 - Increase STIMULAN sales





Infection market

Medical device suppliers are now focusing on infection as a growth opportunity

- Hospitals are under increased scrutiny to provide high quality care, reduce patient readmissions and lower treatment costs
 - There is a growing willingness by surgeons to discuss their infection challenges
 - There is a greater sensitivity to the cost impact of managing infection in patients
- Surgeons are willing to consider absorbable medical devices
- These devices can be segmented into products that are:
 - Supplied with antibiotics
 - Not supplied with antibiotics



Competitor differentiation summary 19-25

Product Name	Formats	Supplied with antibiotics	Elution Rate	Fully Absorbed	Claimed Absorption Rate	Drainage rates	STIMULAN Key points of differentiation
STIMULAN	3 bead sizes, paste, injection	No	Above MIC for 42 days when antibiotics are added	Yes	Approx. 30-60 days (4 - 8 weeks)	0-3.2%	N/A
Collatamp [®] G	3 collagen sponge sizes	Yes - Gentamicin	Above MIC for 7 days	Yes	1 - 7 weeks	Unknown	 Flexible formats May be mixed with antibiotics Optimal absorption rate – leaves no nidus for infection
OSTEOSET® T	1 pellet size	Yes - Tobramycin	Above MIC for 28 days	May not fully absorb	4 - 8 weeks	23-50%	 Flexible formats May be mixed with antibiotics Purity – no impurities as not mined CaSO₄ Fully absorbs Low levels of drainage No third body damage
Cerament [®] G	Moldable paste, beads	Yes - Gentamicin	Above MIC for 28 days	May not fully absorb	6 - 12 months	Unknown	 Flexible formats – includes universal bead mat May be mixed with antibiotics Fully absorbs – no insoluble HA impurities No third body damage

Product profiles



Collatamp G – Aralez[®] Pharmaceuticals Inc., EUSA Pharma[®] EU

Indication & absorption rate^{1,2}

- Indicated for local haemostasis of capillary, parenchymatous and seeping haemorrhages in areas with a high risk of infection
- Claims to absorb within 1-7 weeks

Composition¹

- 2.8mg renatured type-1 bovine collagen per cm²
- 2.0mg gentamicin sulfate per cm²

Formats, sizing and dosage^{1,2}

- Collagen sponge
- Available in 5x5x0.5cm, 10x10x0.5cm and 5x20x0.5cm sizes
- Each size contains 200mg gentamicin sulfate
- May be cut to desired size, rolled to fit into small incisions and sutured in place




Collatamp G

Elution²

- Local dose of 600mg gentamicin stays above MIC for ~ 7 days
- Gentamicin is released by a combination of diffusion and natural enzymatic breakdown of the collagen matrix
- The matrix is fully absorbed within 1-7 weeks according to implant location

Gentamicin Levels Remaining Above MIC in Days



Collatamp G

Take away points¹⁻⁸

- Supplied (pre-loaded) with gentamicin only no Gram-positive coverage
- Should be placed dry on a dry surgical site
- Nidus for infection 7 week absorption time but only above MIC for 7 days
- Short term elution 7 days max but may be faster in a wet environment
- Lack of effectiveness in preventing infections and high re-infection rates reported in literature



OSTEOSET T - Wright Medical[™]

Indication & absorption rate^{9,10}

- Bone void filler that may be used at infected sites
- Claims to absorb within 4-8 weeks

Composition⁹⁻¹²

- OSTEOSET
 - 98.5% surgical grade (mined) calcium sulfate
 - 1.5% stearic acid
- Antibiotic added to form OSTEOSET T
 - 4% tobramycin sulfate by weight

Formats, sizing and setting times^{9,10}

- 4.8mm pellets
- Pellet injector available
- Available in 5, 10 and 20cc vials





Manufacturing^{11,12}






- The patents, technology, and process of producing OSTEOSET were acquired from the United States Gypsum Corporation
- Proprietary manufacturing methods are used to produce a consistent, high-quality material with minimal lot-to-lot variation in chemical and material properties
- OSTEOSET is composed of only 98.5% calcium sulfate

OSTEOSET	CaSO ₄ (98.5%)	CaSO ₄ . ½H ₂ O CaCO ₃ . MgCO ₃ CaCO ₃ Aggregate	` '			
	Calcium Stearate (1.5%)					



Microscopic analysis of purity¹⁷



Insoluble crystalline impurities


OSTEOSET residue



Elution⁹

- Local dose of tobramycin stays above MIC for 22 days in vitro and 28 days in vivo
- Maximum elution occurs within the first day and steadily declines

Tobramycin Levels Remaining Above MIC in Days





Take away points^{9-12,17-26}

- Calcium sulfate component is mined
- Contains non-absorbable impurities and may not fully absorb
- May cause third body damage
- Supplied (pre-loaded) with tobramycin only
- Maximum elution occurs over the first day and rapidly declines
- High wound complication rates reported in literature
- Drainage rates range from 23-50%





Cerament G – Bonesupport®

Indication & absorption rate^{13,14}

- Bone graft substitute indicated to fill bony voids or gaps in the skeletal system
- Claims to absorb within 6-12 months

Composition¹³

- Cerament
 - 40% hydroxyapatite and 60% calcium sulfate
- Antibiotic added to form Cerament G
 - 17.5mg/ml gentamicin
- Mixing liquid
 - 9mg/ml of sodium chloride mixing liquid

Formats, sizing and setting times 13,15,16


- Moldable paste, beads
- Available in 5ml and 10ml kits
- Sets within 20 minutes of mixing





Cerament G

Microscopic analysis of purity¹⁷



Microscopic analysis showing the 40% of HA remaining after calcium sulfate is dissolved.




Cerament G

Elution^{15,17}

- Releases a high localized concentration of gentamicin directly to the surgical site
- Local dose of 175mg gentamicin stays above MIC for ≈ 28 days
- Antibiotic elution is not surface area dependent: injected, beads or molded

Gentamicin Levels Remaining Above MIC in Days





Cerament G

Take away points^{13,15,17}

- Not indicated for use in infected sites
- Includes gentamicin only no gram-positive coverage
- Gentamicin is only added to prevent the device from being colonized with gentamicin sensitive microorganisms
- HA has a slow/incomplete absorption rate (evidence suggests that Cerament residual material remains visible on x-ray two years post-op)
- HA can cause a long-term nidus for infection
- Precaution to avoid intra-articular use
- Long setting times
- No bead mat provided



STIMULAN - Biocomposites

Indication and absorption rate^{17,27-29}

- Approved for placement directly at site of infection in bone voids and defects
- May be mixed with antibiotics
- Fully absorbs within 30-60 days (4-8 weeks)

Composition^{17,27-29}

- 100% pharmaceutical-grade calcium sulfate
- Sterile water

Formats, sizing and setting times 17,27-29

- 3 bead sizes, 2 bullet sizes, paste, injection
- STIMULAN Rapid Cure: 5cc,10cc & 20cc sizes; sets in approximately 4 minutes
- STIMULAN Kit: 5cc & 10cc sizes; sets in approximately 8 minutes
- Included universal bead mat can be used to create 3, 4.8 and 6mm beads
- Bullet mat available to create 7 and 9mm bullets





What makes STIMULAN different?

DRy26TM recrystallization method²⁷






STIMULAN

Antibiotic elution from STIMULAN Rapid Cure^{22,30,31}


 Elution of gentamicin, vancomycin and tobramycin from STIMULAN beads remains over MIC and MBC for 42 days





STIMULAN

Low levels of drainage²⁰⁻²⁶





STIMULAN

Take away points 17,27-29, 31-33

- Controlled purity
- Uniquely engineered through our DRy26 recrystallization method
- Hydrophilic
- Easily mixed with liquid, powder and heat sensitive antibiotics
- Predictable elution profile
- Optimal absorption profile
- Low levels of drainage
- No third body damage
- Used in over 30,000 cases per year
 - Biocomposites offers a comprehensive network of specialists, expert sales representatives and surgeons already using S T I M U L A N to support our customers and hospitals





Increase STIMULAN sales

Strategies and Resources



How do we increase STIMULAN sales?

Key strategies to increase sales

- Understand what makes STIMULAN different
- Establish STIMULAN as a benchmark product
- Educate surgeons that competitor products are not equal substitutes
- Emphasize the importance of results over low prices
- Negative results will cost hospitals additional money
- React quickly
- Perform in-services
- Know what resources to draw on to help you sell STIMULAN






Resources to help you sell STIMULAN

Useful resources

- Comprehensive marketing materials & website
- Distributor Hub & training information
- Large surgeon following
- Surgeon testimonials
- Evidence-based medicine
- Company dedication to innovation, research & resources
- Information Request process



STIMULAN competitive environment

Find out more at biocomposites.com

For indications, contraindications, warnings and precautions see Instructions for Use. The treating physician is responsible for deciding the type and quantity of antibiotic used. Concurrent use of locally administered antibiotics may affect setting time.

The mixing of antibiotics with the STIMULAN Kit/ STIMULAN Rapid Cure device is considered off-label usage of the medicinal product. To do so is at the professional risk of the surgeon / healthcare professional.

This brochure may include the use of STIMULAN or techniques that go beyond the current clearance/ approval granted by the relevant regulatory authority. Please contact your local representative for further information.

©2019, Biocomposites, STIMULAN, Bringing Calcium to Life, Power to Transform Outcomes and DRy26 are trademarks/registered trademarks of Biocomposites Ltd. All rights reserved. No unauthorised copying, reproduction, distributing or republication is allowed unless prior written permission is granted by the owner, Biocomposites Ltd.

Patents granted: GB2367552, EP 1204599 B1, US 6780391, EP 2594231 B1, US 8883063, CN ZL201210466117.X, GB2496710, EP 3058899 B1 Patents pending: GB1502655.2, US 15/040075, CN 201610089710.5, US 15/288328, GB1704688.9, EP 18275044.8, US 15/933936, CN 108619579A

Slides 1,3,11,26 - Images used under license from Shutterstock.com

MA0223R2



STIMULAN competitive environment

References:

- 1. Tribute® Pharmaceuticals Collatamp G order form. M-MK-81 130221.
- 2. https://collatampg.ca/Healthcare_Professionals/About_Collatamp_G/en
- 3. Bennett-Guerrero et al. Effect of an implantable gentamicin-collagen sponge on sternal wound infections following cardiac surgery, A randomized trial. JAMA 2010; vol 304, no 7:755-762.
- 4. Andersson et al. Local administration of antibiotics by gentamicin-collagen sponge does not improve wound healing or reduce recurrence rate after pilonidal excision with primary suture: A prospective randomised controlled trial. Would J Surg 2010; 34:3042-3046.
- 5. Bennett-Guerrero et al. Gentamicin-collagen sponge for infection prophylaxis in colorectal surgery. N Engl J Med 2010; 363;11.
- 6. Marianne Westberg, Frede Frihagen, Ole-Christian Brun et al. Effectiveness of gentamicin-containing collagen sponges for prevention of surgical site infection after hip arthroplasty: A multicentre randomized trial. Clin Infect Dis. 2015; 1752-1759.
- 7. Von Hasselbach C. Klinic und Pharmakokinetic von Kollagen-Gentamicin als Adjuvante Lokaltherapie Knocherner Infektionen. Unfallchirurg 1989:92:459-470.
- 8. Lovering A.M., Sutherland, J., Impact of soaking gentamicin-containing collagen implants on potential antimicrobial efficacy. International Journal of Surgery. 10 (2012) S2-S4.
- 9. Wright Medical Technology, Inc. OSTEOSET® T Medicated Bone Graft Substitute Technical Monograph. 2006 SK651-797 R6.06.
- 10. Wright Medical Technology, Inc. OSTEOSET® T Bone Graft Products 130764-4. November 2010.
- 11. Wright Medical OSTEOSET® Bone Graft Product IFU. October 2013.
- 12. Wright Medical Technology OSTEOSET® BVF Kit 510(K) Summary of Safety and Effectiveness. K010532. 2001.
- 13. Bonesupport Instructions for Use CERAMENTTM G A 0450-01. Document No. IFU 0014-02 EN.
- 14. Bonesupport CERAMENT [™] Bone Void Filler Bone Healing Technical Monograph. PR 0278-02 en EU/US.
- 15. Bonesupport CERAMENT® Antibiotic eluting bone substitutes. PR 0421-04 en EU.
- 16. Bonesupport CERAMENT [™] G Mixing chart. A0443rev08.
- 17. Biocomposites Ltd, Data on File.
- 18. Humm G., Noor S., Bridgeman P., David M., Bose D. Adjuvant treatment of chronic osteomyelitis of the tibia following exogenous trauma using Osteoset® T: A review of 21 patients in a regional trauma centre. Strat Traum Limb Recon. DOI 10.1007/s11751-014-0206-y. 2014. springerlink.com open access article.
- 19. Ferguson J., Diefenbeck M., McNally M., Ceramic biocomposites as biodegradable antibiotic carriers in the treatment of bone infections. J. Bone Joint Infec. 2017;2(1):38-51. doi:10.7150/jbii.17234.



STIMULAN competitive environment

References:

- 20. McPherson, E.J., Dissolvable antibiotic beads in treatment of periprosthetic joint infection. The use of synthetic pure calcium sulfate (Stimulan®) impregnated with vancomycin & tobramycin, in 2nd Annual Oxford Bone Infection Conference (OBIC). 2012: Oxford, UK.
- 21. McPherson, E.J., M.V. Dipane, and S.M. Sherif, Dissolvable antibiotic beads in treatment of periprosthetic joint infection and revision arthroplasty. The use of synthetic pure calcium sulfate (Stimulan®) impregnated with vancomycin & tobramycin. Reconstructive Review, 2013. 3(1): p. 32-43.
- 22. Gauland, C., The use of antibiotic impregnated, implanted synthetic calcium sulphate tablets in the treatment of soft tissue, vancomycin resistant, enterococcus infections. Presented at: Wound Healing Society 2011.
- 23. Borrelli, J., Jr., W.D. Prickett, and W.M. Ricci, Treatment of nonunions and osseous defects with bone graft and calcium sulfate. Clin Orthop Relat Res, 2003;245-54.
- 24. Helgeson, M.D., et al., Antibiotic-impregnated calcium sulfate use in combat-related open fractures. Orthopedics, 2009;32:323.
- 25. McKee, M.D., et al., The use of an antibiotic-impregnated, osteoconductive, bioabsorbable bone substitute in the treatment of infected long bone defects: early results of a prospective trial. J Orthop Trauma, 2002;16:622-7.
- 26. Noor, S., et al., The use of Osteoset-T in the treatment of chronic osteomyelitis of the tibia following exogenous trauma: A review of 22 patients at a regional trauma centre. Bone Joint J 2013;95-B:4.
- 27. Cooper, J.J., Method of producing surgical grade calcium sulphate; Patent. 1999.
- 28. Biocomposites Ltd, STIMULAN Instructions for Use.
- 29. Biocomposites Ltd, STIMULAN Brochure (Canada). MA0033R2. 2017.
- 30. Aiken, S.S., et al., Local Release of Antibiotics for Surgical Site Infection Management Using High-Purity Calcium Sulfate: An In Vitro Elution Study. Surg Infect (Larchmt), 2014.
- 31. Cooper et al. Antibiotic stability in a synthetic calcium sulphate carrier for local delivery. Poster presented at European Bone and Joint Society Annual Meeting, Prague, Czech Republic, 2013.
- 32. Cierny G, DiPasquale D. Comparing Osteoset and Stimulan as antibiotic-loaded, calcium sulfate beads in the management of musculoskeletal infection. Presented at: Musculoskeletal Infection Society of North America 2009.
- 33. Kallala R, Nizam I, Haddad F. Outcomes following use of antibiotic-eluting, absorbable, calcium sulfate beads in revision hip and knee surgery for periprosthetic infection. Presented at: International Society for Technology in Arthroplasty 2013.

